Skip to main content
    S

    Syndax Pharmaceuticals Inc (SNDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.20
    +0.07 (+0.77%)

    Market Cap: $850.77M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Syndax Pharmaceuticals Inc (SNDX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Syndax Pharmaceuticals (SNDX) has a market cap of $850.77M and an enterprise value of $959.62M. Revenue grew 159.46% over the last 12 months from the 12 months before. It kept -72.38% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 12.79% above the market cap, as debt exceeds cash.

    Market Cap$850.77M
    Enterprise Value$959.62M
    Latest price (Nov 17, 2026)$9.20

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 2, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.90% in the quarter ended Sep 30, 2026 and grew 2.52% a year over 2 years.

    Shares Outstanding89.79M
    Shares Change (YoY)+3.66%
    Shares Change (QoQ)+0.90%
    Share Count Growth (2Y CAGR)+2.52%

    Valuation Ratios

    The price to sales ratio is 2.9x. Its year-end P/S ranged from 8.3x to 597.7x from 2016 to 2025.

    P/S Ratio2.9x
    Forward P/S2.7x

    Price Statistics

    The stock is down 44.65% over 52 weeks and trades 37.96% below its 50-day average.

    Beta (1Y)0.78
    52-Week Change-44.65%
    1-Month Change-29.72%
    3-Month Change-55.71%
    6-Month Change-52.48%
    5-Year Change-29.82%
    10-Year Change+15.58%
    Total Return (1Y)-44.65%
    Total Return (3Y CAGR)-15.54%
    Total Return (5Y CAGR)-12.42%
    Return vs SPY (1Y)-57.73%
    Max Drawdown (1Y)-63.70%
    Max Drawdown (3Y)-64.81%
    Sharpe Ratio (1Y)-1.05
    Correlation with SPY (1Y)0.18
    50-Day Average$14.83
    200-Day Average$19.61
    52-Week Range$9.06 to $25.59
    RSI (14 Days)25.8
    Average Volume (20 Days)3.95M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.69x current liabilities.

    Current Ratio4.69x
    Quick Ratio4.37x
    Interest Coverage-4.77x

    Returns and Efficiency

    Return on invested capital is -65.05% over the last 12 months.

    Return on Assets (ROA)-30.24%
    Return on Invested Capital (ROIC)-65.05%
    Return on Capital Employed (ROCE)-32.78%
    ROA (5Y Average)-31.30%
    Asset Turnover0.47x
    Inventory Turnover0.62x
    Receivables Turnover6.07x
    Cash Conversion Cycle579 days

    Scores

    SNDX has an Altman Z-Score of -2.33, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score-2.33
    Altman Z ZoneDistress
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $289.43M over the last 12 months.

    Revenue$289.43M
    Revenue Growth (YoY)+159.46%
    Gross Profit$266.89M
    Operating Income-$178.64M
    Pretax Income-$209.48M
    Net Income-$209.48M
    EBIT-$187.41M
    Reported EPS (TTM)-$2.36

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$135.94M
    Total Debt$244.79M
    Net Debt$108.85M
    Net Debt Per Share$1.21
    Working Capital$446.47M
    Shareholder Equity-$17.18M
    Total Assets$692.67M
    Total Liabilities$709.85M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$177.36M
    FCF Per Share-$2.00
    Depreciation and Amortization$4.17M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -61.72%.

    Gross Margin92.21%
    Operating Margin-61.72%
    Pretax Margin-72.38%
    Net Margin-72.38%
    EBIT Margin-64.75%

    Growth

    Revenue Growth (5Y CAGR)+157.68%
    Book Value Per Share Growth (2Y CAGR)-68.75%
    Tangible Book Per Share Growth (2Y CAGR)-68.75%

    Revenue and profit by year

    Dividends and Yields

    SNDX does not pay a dividend.

    Buyback Yield-0.15%
    Shareholder Yield-0.15%

    Peer Position

    Against 4 similar companies, SNDX has the 4th highest P/S.

    P/S Ratio2.9x vs 18.7x median
    ROIC-65.05% vs -32.76% median
    Revenue Growth (Trailing 4 Quarters, YoY)+159.46% vs -100.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 63.15% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+63.15%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SNDX

    What is SNDX's market cap?

    Syndax Pharmaceuticals has a market cap of $850.77M. Its enterprise value, which adds debt and subtracts cash, is $959.62M.

    How many shares of SNDX are outstanding?

    Syndax Pharmaceuticals has 89.79M shares outstanding. The count is up 3.66% from a year earlier.

    Does SNDX pay a dividend?

    No. Syndax Pharmaceuticals does not pay a dividend.

    How much debt does SNDX have?

    Syndax Pharmaceuticals has $244.79M of total debt and $135.94M of cash and equivalents, a net debt position of $108.85M.